Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-01

Study Completion Date

2025-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To explore the effectiveness and safety of Zanuburutinib in relapsed and refractory idiopathic Multicentric Castleman's disease (iMCD) patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients

NCT05356858

Neuromyelitis Optica

UNKNOWN PHASE2

Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease

NCT04838860

Idiopathic Multicentric Castleman's Disease

TERMINATED PHASE2

Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related Polyneuropathy

NCT05939037

Monoclonal Gammopathy of Uncertain Significance

RECRUITING PHASE2

Study of CM310 in Healthy Subjects

NCT06161090

Healthy

COMPLETED PHASE1

Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders

NCT05891379

Neuromyelitis Optica Spectrum Disorder

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a single center, open-labeled , single arm, prospective study which includes a safety run-in phase. The primary endpoint is the overall response rate which includes complete response (CR) and partial response (PR) at Week 12 and Week 24. The secondary endpoints include progression-free survival (PFS), overall survival (OS), and adverse events. There are two phases of the study. The first phase is the 'safety run-in phase'which plans to enroll 6 patients who would be observed for safety issues for 12 weeks after study drug administration. If no Grade ≥ 4 (CTCAE) adverse events (AE) occurs during this phase, the study would enter the second phase; if Grade ≥ 4 (CTCAE) AE happens during this phase, the study would be terminated. In the second phase of the study, another 24 patients would be enrolled. All enrolled patients would receive the study drug until progression of disease, intolerability of the drugs or Week 96 and would be followed every 4 weeks in the first 12 weeks, every 12 weeks until Week 48 and every 24 weeks until Week 96. The follow-up phase to assess PFS and OS will last from initiation of study drug to 36 months after enrollment (evaluation would be carried out every 24 weeks after Week 96). The total study duration will be 4 years after the last patient starts study medication.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Idiopathic Multicentric Castleman's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

This will be a single center, single arm, phase 2 study.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

This will be an open label study.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Zanuburutinib

Oral Zanuburutinib 160mg twice a day

Group Type EXPERIMENTAL

Zanubrutinib

Intervention Type DRUG

Oral Zanuburutinib, 160mg twice a day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Zanubrutinib

Oral Zanuburutinib, 160mg twice a day

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

brukinsa

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* fulfilled the CDCN (Castleman Disease Collaborative Network) diagnostic criteria of iMCD
* relapsed or refractory disease. Relapsed = patients who ever achieved overall partial response (PR) or complete response (CR) with prior lines of therapy suffered from progressive disease (PD); refractory = iMCD patients who never achieved PR or CR with the first-line treatment but suffered from PD during treatment.
* Eastern Cooperative Oncology Group performance status (ECOG-PS ≤ 2)
* Neutrophil count ≥ 0.75×10\^9/L, hemoglobin ≥ 70 g/L and platelet count \> 30×10\^9/L
* Total bilirubin ≤ 2 x ULN (upper limit of normal), AST（aspartate aminotransferase） or ALT（Alanine aminotransferase）≤ 2.5 x ULN
* INR （international normalized ratio) and APTT(activated partial thromboplastin time) ≤ 1.5 x ULN；eGFR\>25ml/min/1.73m2
* estimated survival ≥ 3 months
* agree to take birth control methods during study period for women of reproductive age
* agree to provide informed consent

Exclusion Criteria

* concurrent malignancies
* prior history of receiving any kind of BTK (Bruton's tyrosine kinase) inhibitors
* patients with SLE (systemic lupus erythematosus), HHV-8 (human herpesvirus-8) infection or POEMS syndrome
* History of major surgery or radiation therapy within 4 weeks before initiation of study drug
* history of myocardial infarction within 1 years
* patient with history of heart failure (NYHA 3 or 4) would be excluded unless his LVEF(left ventricular ejection fraction) ≥ 50% within 1 months
* primary cardiomyopathy; Qtc \> 450ms for men and \> 470ms for women
* breast feeding or pregnant women
* intolerance for oral regimen due to gastro-intestinal disorders
* uncontrolled infection
* positive HBV(hepatitis B virus)-DNA titers or positive HbsAg; positive HCV(hepatitis C virus)antibody; patients with HIV infection
* patients with history of bleeding disorders
* cerebral infarction or intracranial bleeding within 6 months
* active bleeding disorders within 2 months
* taking anti-platelet or anticoagulation drugs
* taking drugs which strongly inhibit P450 CYP3A
* patients or their relatives fail to understand the purpose of the study
* any other conditions that the investigators consider to be not appropriate for inclusion

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No